Tyra Biosciences, Inc. (TYRA): Price and Financial Metrics

Tyra Biosciences, Inc. (TYRA): $16.52

1.02 (+6.58%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add TYRA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#243 of 360

in industry

TYRA Price/Volume Stats

Current price $16.52 52-week high $20.67
Prev. close $15.50 52-week low $10.38
Day low $15.53 Volume 51,201
Day high $17.59 Avg. volume 130,387
50-day MA $17.65 Dividend yield N/A
200-day MA $14.81 Market Cap 867.70M

TYRA Stock Price Chart Interactive Chart >


Tyra Biosciences, Inc. (TYRA) Company Bio


Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.


TYRA Latest News Stream


Event/Time News Detail
Loading, please wait...

TYRA Latest Social Stream


Loading social stream, please wait...

View Full TYRA Social Stream

Latest TYRA News From Around the Web

Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.

Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the 2023 Jefferies London Healthcare Conference, taking place November 14-16, 2023.

Yahoo | November 8, 2023

Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2023 and highlighted recent corporate progress.

Yahoo | November 7, 2023

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings.

Yahoo | September 21, 2023

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | September 17, 2023

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at the 2023 Cantor Global Healthcare Conference, taking place September 26-28, 2023, in New York, NY.

Yahoo | September 12, 2023

Read More 'TYRA' Stories Here

TYRA Price Returns

1-mo -1.20%
3-mo 30.28%
6-mo 50.05%
1-year 31.01%
3-year N/A
5-year N/A
YTD 19.28%
2023 82.24%
2022 -45.98%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!